2023
Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast Cancer
Liedtke C, Mazouni C, Hess K, André F, Tordai A, Mejia J, Symmans W, Gonzalez-Angulo A, Hennessy B, Green M, Cristofanilli M, Hortobagyi G, Pusztai L. Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast Cancer. Journal Of Clinical Oncology 2023, 41: 1809-1815. PMID: 36989609, DOI: 10.1200/jco.22.02572.Peer-Reviewed Original ResearchTriple-negative breast cancerPathologic complete response rateNeoadjuvant chemotherapyResidual diseaseBreast cancerProgesterone receptorEstrogen receptorHuman epidermal growth factor receptor 2 (HER2) expressionSurvival rateEpidermal growth factor receptor 2 expressionProgression-free survival ratesM.D. Anderson Cancer CenterComplete response rateOverall survival rateAnderson Cancer CenterReceptor 2 expressionLong-term survivalBone recurrenceNeoadjuvant therapyPostrecurrence survivalVisceral metastasesWorse OSWorse survivalRelapse rateCancer Center
2011
S1-7: Molecular Tumor Characteristics Influence Adjuvant Endocrine Treatment Outcome.
Bianchini G, Pusztai L, Iwamoto T, Kelly C, Zambetti M, Fasolo A, Del Conte G, Santarpia L, Symmans W, Gianni L. S1-7: Molecular Tumor Characteristics Influence Adjuvant Endocrine Treatment Outcome. Cancer Research 2011, 71: s1-7-s1-7. DOI: 10.1158/0008-5472.sabcs11-s1-7.Peer-Reviewed Original ResearchDistant relapse ratesPatterns of relapseAromatase inhibitorsLate relapseRelapse rateHigh riskTime cohortsEstrogen receptor-positive casesOncotype DX recurrence scoreAdjuvant clinical trialsEndocrine-sensitive cancersEndocrine-sensitive tumorsLow-proliferation tumorYears of tamoxifenNode-negative tumorsReceptor-positive casesUse of tamoxifenDX recurrence scoreBiomarker groupsEndocrine therapyEndocrine drugsEarly relapseEndocrine resistanceLate recurrenceRisk stratification
2008
Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast Cancer
Liedtke C, Mazouni C, Hess KR, André F, Tordai A, Mejia JA, Symmans WF, Gonzalez-Angulo AM, Hennessy B, Green M, Cristofanilli M, Hortobagyi GN, Pusztai L. Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast Cancer. Journal Of Clinical Oncology 2008, 26: 1275-1281. PMID: 18250347, DOI: 10.1200/jco.2007.14.4147.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsBreast NeoplasmsCarcinoma, Ductal, BreastChemotherapy, AdjuvantFemaleHumansMiddle AgedNeoadjuvant TherapyNeoplasm Recurrence, LocalNeoplasm StagingNeoplasm, ResidualNeoplasms, Hormone-DependentPrognosisProspective StudiesReceptor, ErbB-2Receptors, EstrogenReceptors, ProgesteroneSurvival RateConceptsTriple-negative breast cancerPathologic complete response rateNeoadjuvant chemotherapyResidual diseaseBreast cancerProgesterone receptorEstrogen receptorHuman epidermal growth factor receptor 2 (HER2) expressionSurvival rateEpidermal growth factor receptor 2 expressionProgression-free survival ratesM.D. Anderson Cancer CenterComplete response rateOverall survival rateAnderson Cancer CenterReceptor 2 expressionLong-term survivalBone recurrenceNeoadjuvant therapyPostrecurrence survivalVisceral metastasesWorse OSWorse survivalRelapse rateCancer Center